file_name,predicted_questionnaires,predicted_timepoints,Sponsor,TherapeuticArea,ground_truth_questionnaires,ground_truth_timepoints,Unnamed: 5,match_count,precision,recall,f1_score,matched_items,unmatched_predictions,unmatched_ground_truth
Protocol_01,"['Dermatology Life Quality Index (DLQI)', 'PSO-TARGET Quality of Life Component Grid (PSO-TARGET)']","['Base-line Visit (Day 0)', '3 months Visit (week 12-16)', '12 months visit (week 48-56)', 'Base-line Visit (Day 0)', '3 months Visit (week 12-16)', '12 months visit (week 48-56)']",LEO Pharma France,Dermatogoly,"['Dermatology Life Quality Index (DLQI)', 'PSO-TARGET Quality of Life Component Grid (PSO-TARGET QoL Component Grid)']","['Base-line Visit (Day 0)', '3 months Visit (week 12-16)', '12 months visit (week 48-56)', 'Base-line Visit (Day 0)', '3 months Visit (week 12-16)', '12 months visit (week 48-56)']",Psoriasis area and severity index (PASI) (Not marked as PROs in protocol),2.0,1.0,1.0,1.0,"['Dermatology Life Quality Index (DLQI) -> Dermatology Life Quality Index (DLQI) (1.00)', 'PSO-TARGET Quality of Life Component Grid (PSO-TARGET) -> PSO-TARGET Quality of Life Component Grid (PSO-TARGET QoL Component Grid) (0.96)']",[],[]
Protocol_02,['Functional Assessment of Cancer Therapy - General (FACT-G)'],"['Cycle 4', 'Treatment Discontinuation', 'Off Study']","National Cancer Institute 
",Oncology,['Functional Assessment of Cancer Therapy-General (FACT-G)'],"['Cycle 1', 'Cycle 4', 'Treatment Discontinuation', 'Off Study']",,1.0,1.0,1.0,1.0,['Functional Assessment of Cancer Therapy - General (FACT-G) -> Functional Assessment of Cancer Therapy-General (FACT-G) (1.00)'],[],[]
